Celiac Disease Market Size Set to Prosper at a CAGR of 9.18% During the Study Period 2018-2030 in the 7MM | DelveInsight

LAS VEGAS, April 27, 2021 /PRNewswire/ -- DelveInsight's Celiac Disease Market Insights report offers detailed information on current treatment practices, emerging drugs, Celiac Disease market share of the individual therapies, current and forecasted Celiac Disease market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

The report also covers the present Celiac Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs that help clients curate the best of the opportunities and assess the market's underlying potential, and plans strategically to tackle market risks.

Key takeaways from the Celiac Disease Market Insights report: 

• The total Celiac Disease prevalent population in the 7MM was 6,450,607 in 2020. It is further expected to increase at a CAGR of 0.53% during the study period (2018–2030).
• The current mainstay of the treatment for Celiac Disease is mainly dominated by a gluten-free diet (GFD) to avoid an immunological cascade. 
• Celiac Disease emerging therapies include Larazotide Acetate (9 Meters Biopharma), Latiglutenase/IMGX003 (Immuno-genX), PRV-015 (Provention Bio), and CNP-101/ TAK-101 (Takeda/ Cour Pharma).
• Key companies energetically driving the Celiac Disease market size growth forward include ImmunoGenX, Takeda, 9 Meters Biopharma, Provention Bio, among several others. 
• The highest Celiac Disease market size was accounted by the United States, which is anticipated to increase with a CAGR of 9.47%% in the foreseeable future. 
• The least share of the Celiac Disease market was occupied by Japan across the 7MM.
• Out of all the Celiac Disease pipeline therapies, Larazotide Acetate appears to be the most promising owing to a higher probability of success as compared to other emerging therapies, largest patient share, and impressive improvement in average on-treatment Celiac Disease Gastrointestinal Symptom Rating Scale (GSRS) score. 9 Meters Biopharma plans to file for conditional approval of the drug.
• Latiglutenase and TAK-101 are also in the race with impressive success rates; wherein Immuno-genX recently completed its Celiac Shield Phase II trial and is looking forward to conducting further trials for evaluation. Whereas Takeda's TAK-101 requires more robust data in a large patient pool for further assessment. 
• Takeda's TAK-101 in the investigative phase II trial had the lowest number of patients, i.e., 34 participants in the study. Recently Takeda initiated a dose-ranging Phase II trial with 134 patient to prevent Gluten-Specific T Cell Activation in CD patients.
• All the emerging therapies are under investigation in adjunction with the first-line therapy of the treatment that is a gluten-free diet. Thus, GFD is set to dominate the market even after the approval of therapies. 
• However, this offers a brilliant opportunity to pharmaceutical companies to develop novel curative therapy and enjoy the monopoly in the Celiac Disease market. 

Learn more about the report highlights through sample report @ Celiac Disease Market Analysis and Forecast 

Celiac disease is one of the most common intolerances. Going by the data presented by several studies, it affects approximately 1% of the global population. Further, several 

As per DelveInsight's analysis, Celiac Disease prevalence was reported to be maximum in the US, which is further anticipated to increase modestly. 

Celiac Disease Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM spanning the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan segmented into:

• Total Celiac Disease Prevalent Population 
• Total Diagnosed Celiac Disease Prevalent Population 
• Gender-specific Celiac Disease Prevalent Population 
• Type-specific Celiac Disease Prevalent Population
• Age-specific Celiac Disease Distribution 

For a comprehensive analysis, visit Celiac Disease Epidemiology Trends 

Celiac Disease Treatment Market 

The Celiac Disease treatment usually focuses on excluding foods that contain gluten from the diet. A gluten-free diet (GFD) helps to prevent damage to the lining of the intestines (gut) and also helps in preventing the associated symptoms, such as diarrhea and stomach pain. With GFD, it is observed that symptoms improve considerably. Besides, certain supplements (vitamin and mineral supplements) are also available. 

Reach out to us @ Celiac Disease Marketed Therapies for more information on available treatment regimens 

Celiac Disease Market 

At the moment, there is no cure in the Celiac Disease market, and there remains a huge unmet need in the market in the form of limitations to GFD. Despite being safe and effective, a gluten-free diet is not ideal and requires life-long adherence. The condition is also reported to relapse even when the patient is of GFD. Besides standard therapies, there is also a requirement for better diagnostics methodologies to solve the issue of differential diagnosis. 

However, owing to key companies working in the Celiac Disease market and the launch of pipeline therapies, the landscape of the Celiac Disease market is ascribed to transform during the forecast period of 2021–2030. However, the dominance of GFDs and the investigation of pipeline therapies as adjunctive therapy with GFD is expected to majorly contribute towards the growth of the Celiac Disease market size growth. 

Celiac Disease Pipeline Therapies 

• Larazotide Acetate: 9 Meters Biopharma
• Latiglutenase/IMGX003: Immuno-genX
• PRV-015: Provention Bio
• CNP-101/ TAK-101: Takeda/ Cour Pharma

Scope of the Report 

Coverage: 7MM (the US, EU5, and Japan)

Study Period: 2018-30

Key Companies: 9 Meters Biopharma, Immuno-genX, Provention Bio, Takeda, Cour Pharma, among others.

Key Celiac Disease Pipeline Therapies: Larazotide Acetate, Latiglutenase/IMGX003, PRV-015, CNP-101/ TAK-101, among others. 

Celiac Disease Market Segmentation: By Geography, By Celiac Disease Therapies

Analysis: Comparative and conjoint analysis of Celiac Disease emerging therapies

Tools used: SWOT analysis, Conjoint Analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.

Case Studies

KOL's Views

Analyst's Views

Drop by to learn more about the future market trends @ Celiac Disease Market Landscape and Forecast 

Table of Contents 

Discuss the evolving trends of market landscape @ Celiac Disease Market Forecast 

Browse Through Related Reports 

Global Messenger RNA Market

DelveInsight's 'Global Messenger RNA (mRNA)-based Vaccines and Therapeutics – Market Insights, Epidemiology, and Market Forecast—2030' report.

Anti Hypertension Market

DelveInsight's "Anti-hypertension - Market Insights, Epidemiology, and Market Forecast-2030" report. 

Adult Myopia Market

DelveInsight's 'Adult Myopia – Market Insights, Epidemiology, and Market Forecast—2030' report.

Moderate To Severe Atopic Dermatitis Market

DelveInsight's "Moderate to Severe Atopic Dermatitis (AD) - Market Insights, Epidemiology, and Market Forecast-2030" report.

Abdominal Aortic Aneurysm Market

DelveInsight's "Abdominal Aortic Aneurysm - Market Insights, Epidemiology, and Market Forecast-2030" report.

Abscess Market

DelveInsight's "Abscess - Market Insights, Epidemiology, and Market Forecast-2030" report.

Read more about ABSSSI Market and the key companies including Innovation Pharmaceuticals, Motif Bio, Basilea Pharmaceutica, Debiopharm, Destiny Pharma, KBP Biosciences, MicuRx Pharmaceuticals and others advancing the ABSSSI pipeline.

Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare and Biotech News 

Contact Us

Shruti Thakur 
[email protected] 
+1(919)321-6187 
www.delveinsight.com

SOURCE DelveInsight Business Research, LLP